Novo Nordisk’s Real World Data Strategy Lead, Tom Dougherty, walks through clinical trial tokenization: where it is being used, why it’s such a potential value-add to trials and programs, and what life science organizations must consider when preparing for the inclusion of tokenization.
Lead Editorial
